FIG. 2.
Change in tumor size in 14 patients with BRAFV600E-mutant thyroid cancer treated with dabrafenib. *, patient received prior MEK inhibitor treatment; †, patient with concurrent papillary and Hurthle cell features; #, patient received 100 mg TID. All other patients received 150 mg BID. ‡, patient with anaplastic histology. This patient had a 66% decrease in target lesions but developed a new lesion at first restaging. Note 1: One patient withdrew consent before having any post-baseline disease assessment, so was not included in the plot. Note 2: The patient with the largest reduction experienced reduction in her target lesion but disease progression in a non-target lesion at the same disease assessment. Subsequent biopsy of the progressing non-target lesion demonstrated anaplastic carcinoma histology, rather than papillary carcinoma.